arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Forte Biosciences, Inc.

FBRX
$76.80 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
43 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Forte Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -54.2%
FCF / Share None
Trailing P/E
Price / Book 25.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

43-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.00K
↓ -100.0%
Net Income Profit after all expenses
$-22.14M
↓ -41.4%
Long-Term Debt Long-term obligations
$22.08M
↓ -8.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Cash Quality
50

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 43 quarters